SUMO2P15

Across TCGA pan-cancer cohorts, SUMO2P15 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated SUMO2P15 data layer.

The strongest signal is observed in uveal melanoma (UVM), where higher SUMO2P15 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUMO2P15 expression acts as an unfavorable survival marker, although some lineages such as LIHC and LUSC show a favorable association.

UVM, LIHC, and KICH are the cancer types where SUMO2P15 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Quartile	II,III,IV	0.443	0.808	.001	93	view →
LIHC	OS	Tertile	All	0.934	0.707	.005	66	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	45	view →
LUSC	DFS	Tertile	All	0.696	0.419	.005	31	view →
THCA	OS	Quartile	IV	0.554	0.932	.002	31	view →
READ	OS	Tertile	IV	0.333	0.769	.002	18	view →
PCPG	OS	Quartile	All	0.699	0.983	.009	14	view →
SKCM	DFS	Tertile	IV	0.045	0.471	.016	12	view →
THYM	OS	Quartile	II,III,IV	0.584	0.902	.005	11	view →
BLCA	OS	Tertile	IV	0.310	0.619	.018	9	view →
BRCA	DFS	Median	III,IV	0.570	0.429	.036	9	view →
COAD	OS	Tertile	II,III,IV	0.401	0.630	.022	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

SUMO2P15–UVM (DFS)

Open the UVM breakdown →